

Special Issue

New Trends in Hepatocellular Carcinoma: Artificial Intelligence, Robotics and Innovative Treatments

Message from the Guest Editor

Hepatocellular carcinoma is a worldwide issue, and treatment has rapidly evolved in the recent years. Its prevalence and aetiology vary in different countries, but the incidence is increasing worldwide. Treatment and strategies are complex, with a wide range of medical and surgical solutions often combined, but frequently used differently and in different fashions according to countries, regions, hospitals, and even medical teams. These variations reflect the combined presence of a complex neoplastic disease almost constantly associated with cirrhosis, necessitating a single strategy to treat two diseases at a time. Evolutions in immunotherapy and chemotherapy, technical innovations such as the R.A.P.I.D. technique in liver transplantation, the use of indocyanine green during liver resection, the progressive widespread of robotics, and the emerging role of artificial intelligence are changing the standard paradigms and opening new frontiers to future developments. The real benefits of these innovations are still under investigation, but precision medicine and precision surgery has become a cornerstone concept in the management of the disease.

Guest Editor

Dr. Emanuele Felli

Service Chirurgie Digestive et Transplantation Hépatique, Hôpital Trousseau CHU, 37170 Tours, France

Deadline for manuscript submissions

closed (28 February 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/178381

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)